VANCOUVER, British Columbia & GRAPEVINE, Texas — Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on April 14, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 20,000 shares of common stock to a new non-executive employee under the Company’s 2026 Inducement Grant Plan. The 2026 Inducement Grant Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company. The Compensation Committee approved the stock options as an inducement material to such new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
